‘Awakening the Inner Light' Explores Introspection and Identity Through Contemporary Art
'
Awakening the Inner Light
'
is offering viewers a contemplative journey through paintings and photographs that examine the inner workings of self, memory, and resilience. On display this week, the exhibition brings together fifteen contemporary artists whose works explore deeply personal and spiritual terrains.
Spanning abstract canvases, textured surfaces, and symbolic portraits, the show meditates on themes of transformation, silence, and cultural memory. From rooftops of childhood rendered in evocative tones to photographs capturing raw emotional stillness, the exhibition becomes a space where visual storytelling meets quiet introspection.
The artists—including names such as Akansha Chaturvedi, Anupama Singh, Dharmendra Rathore, Lorraine Thiria, and Moonmoon Bhagchandika, among others—reflect on the invisible threads that connect consciousness, identity, and belonging.
Light emerges not just as an aesthetic device, but as a recurring metaphor for clarity, resistance, and renewal.
Curator Ranbir Rathi describes the show as a recognition of 'awakening' not as a final destination, but as an evolving and often imperfect process. 'The inner light is not about reaching enlightenment in the traditional sense,' he explains. 'It's about honouring the courage and clarity that already reside within us.'
One of the standout moments of the exhibition is a powerful self-portrait of a woman captured in a ritual gesture—both vulnerable and commanding—anchoring the viewer in themes of embodiment and inner strength. Elsewhere, urban textures, ritual symbolism, and quiet landscapes invite layered interpretations.
'Awakening the Inner Light'
doesn't preach—it prompts. In a time marked by distraction and disconnection, the exhibition urges visitors to pause, reflect, and reconnect with the quiet, persistent light within.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Alonso's Real Madrid start La Liga with fresh energy
Real Madrid, featuring several new signings, approach the new season with fresh hope under recently-appointed coach Xabi Alonso, looking to turn the page on a disappointing end to the Carlo Ancelotti era with "ambitious" football. Former Liverpool and Los Blancos midfielder Alonso saw at the Club World Cup in the United States this summer there is plenty of work to do, as Paris Saint-Germain thrashed Madrid 4-0 in the semi-final. "Things are going to be different... we are starting from scratch," said Alonso, although some of his findings from the tournament will undoubtedly influence his approach. Madrid fans also got their first glimpse of the Basque tactician's plans, and also of England defender Trent Alexander-Arnold. Alonso showed tactical flexibility, utilising both a four-man and three-man defence, whereas his predecessor Ancelotti tended to stick with four at the back and was criticised for not being adaptive enough in games. By contrast Alonso was keen to adjust things during matches if he could, including the positioning of his players, and keen to impress on his squad they must all help defensively and with pressing. "We need and want everyone to defend -- the 11 players on the pitch have to be involved defensively," said Alonso during the tournament, asked specifically about star forwards Vinicius Junior and Kylian Mbappe. "They have to know how we want to press, and without that, things will be very complicated," continued Alonso. "Vini, Jude (Bellingham), Fede (Valverde), Kylian, those up front, the defence has to push forward too." Alonso is looking to obtain the balance that Ancelotti failed to achieve last season following Mbappe's arrival from PSG. Although the French superstar struck 43 goals under Ancelotti it was not enough to inspire a Madrid side that finished the season without a major trophy, while Barcelona reclaimed La Liga as part of a domestic treble. Mbappe's illness with a stomach bug kept him out of Madrid's group matches at the Club World Cup, but on his first start was in the destruction by PSG. "We have to be self-critical, but it will also serve us as a guide for where we need to improve," said Alonso. If Alonso can find the formula for Mbappe and Vinicius to work together without sacrificing too much out of possession remains to be seen, while winger Rodrygo Goes does not appear to be part of the coach's plans, playing a bit-part role in the States. - Goodbyes and new faces - Madrid go into the season without Luka Modric in the squad for the first time in over a decade, with the Croatian's experience and quality a big miss for a side lacking some guile in midfield. Los Blancos' hope is for Turkish playmaker Arda Guler to be able to thrive there and become a player who can control the tempo of a game. "The coach is trying to make us have more control of the game, and that's better for me," said Guler. The 20-year-old should get plenty of chances to play at the start of the season with Jude Bellingham sidelined until around mid-October after shoulder surgery to solve a long-running issue. By then new arrival and fellow England international Alexander-Arnold may have established himself in the side. The full-back, who joined from Liverpool before the end of his contract so he could play at the Club World Cup, adds further attacking quality to a Madrid squad brimming with it. Madrid hope Dean Huijsen could help solve some issues at the back, while Alvaro Carreras and Franco Mastantuono also join, with Los Blancos spending over 170 million euros ($200 million) this summer. Dani Carvajal's return from a long-term knee injury is another piece of good news for a Madrid side who need it after their 2024-25 campaign was more noteworthy for the club's attacks on referees than for success on the field. Alonso, who hopes to play an "ambitious" game with "emotion and energy", wants the world to be talking about Real Madrid's football once again. rbs/mw
Yahoo
3 minutes ago
- Yahoo
Morning Bid: Bitcoin joins the risk-on party
A look at the day ahead in European and global markets from Ankur Banerjee You know markets are fully risk-on when cryptocurrencies are on a tear, with bitcoin joining global stocks to scale a record peak as the near certainty of U.S. interest rate cuts bolsters risk sentiment and weighs on the dollar. The world's best-known cryptocurrency, bitcoin, has a lot going for it: prospects of lower interest rates, a more favourable regulatory environment, and bullish inflows from institutional investors. Ether too has been on the charge, hovering near its highest since November 2021, becoming the token of choice for those looking for more active returns. In fact, ether is up 42% this year, outstripping the 32% gain for bitcoin. Stocks in Asia were taking a bit of a breather after a blistering rally this week. Japanese shares fell after hitting a record high, while tech-heavy Taiwan and South Korean shares eased after recent highs. Investors are wagering that the Federal Reserve will resume cutting interest rates from next month, with traders starting to even price in odds of a 50 basis points cut after comments from Treasury Secretary Scott Bessent. "If we'd seen those numbers in May, in June, I suspect we could have had rate cuts in June and July. So that tells me that there's a very good chance of a 50 basis-point rate cut," in September, Bessent said in an interview on Bloomberg Television. Fed Chair Jerome Powell, who has been regularly lambasted by U.S. President Donald Trump, is expected to speak at a central bank research conference in Wyoming next week and the focus will be on his tone on policy path. Bessent also said the Bank of Japan will likely be raising interest rates as it is behind the curve in dealing with the risk of inflation, leading to strong gains in the yen, which stayed around its strongest level in three weeks. Investor focus during European hours will be on a swathe of economic data that will offer a glimpse of the tariff uncertainties and the impact of the duties on the economy. Key developments that could influence markets on Thursday: Economic events: Euro zone flash GDP for Q2, UK prelim GDP for Q2 (By Ankur Banerjee; Editing by Muralikumar Anantharaman)
Yahoo
3 minutes ago
- Yahoo
Asian Growth Stocks With Insider Ownership Expecting Up To 93% Earnings Growth
As Asian markets experience a period of growth, bolstered by strong corporate earnings and resilient economic indicators, investors are increasingly focusing on companies with robust insider ownership. In this environment, stocks that combine high insider stakes with significant expected earnings growth can present compelling opportunities for those seeking to align their interests with company insiders who have a vested interest in the firm's success. Top 10 Growth Companies With High Insider Ownership In Asia Name Insider Ownership Earnings Growth Vuno (KOSDAQ:A338220) 15.6% 109.8% Techwing (KOSDAQ:A089030) 19.1% 68% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Sineng ElectricLtd (SZSE:300827) 36% 25.8% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 24.3% Novoray (SHSE:688300) 23.6% 28.2% M31 Technology (TPEX:6643) 30.8% 95.5% Laopu Gold (SEHK:6181) 35.5% 43% Gold Circuit Electronics (TWSE:2368) 31.4% 32.8% Fulin Precision (SZSE:300432) 12.8% 43.7% Click here to see the full list of 593 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Let's explore several standout options from the results in the screener. RemeGen Simply Wall St Growth Rating: ★★★★★★ Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$40.14 billion. Operations: RemeGen's revenue from biopharmaceutical research, service, production, and sales amounts to approximately CN¥1.91 billion. Insider Ownership: 11.2% Earnings Growth Forecast: 66.3% p.a. RemeGen is experiencing significant growth, with earnings forecasted to grow 66.34% annually and revenue expected to increase by 24.6% per year, outpacing the Hong Kong market. Despite high share price volatility, it trades at a notable discount below its estimated fair value. Recent developments include FDA clearance for clinical trials of RC148 in the US and a global Phase 3 trial for Telitacicept, highlighting its innovative drug pipeline and potential for future expansion in international markets. Unlock comprehensive insights into our analysis of RemeGen stock in this growth report. Our comprehensive valuation report raises the possibility that RemeGen is priced higher than what may be justified by its financials. Anhui Estone Materials TechnologyLtd Simply Wall St Growth Rating: ★★★★★☆ Overview: Anhui Estone Materials Technology Co., Ltd specializes in lithium battery coating, electronic communication functional filling, and low-smoke halogen-free flame-retardant materials in China with a market cap of CN¥5.24 billion. Operations: The company generates revenue of CN¥510.72 million from its specialty chemicals segment. Insider Ownership: 32.8% Earnings Growth Forecast: 60.8% p.a. Anhui Estone Materials Technology Ltd. is projected to see robust expansion, with earnings anticipated to grow 60.8% annually and revenue expected to rise by 23.7% per year, surpassing the Chinese market's growth rates. The company recently turned profitable but faces challenges from large one-off items affecting its financial results. Despite these hurdles, no substantial insider trading activity has been reported in recent months, indicating stability in insider sentiment toward the company's prospects. Click here to discover the nuances of Anhui Estone Materials TechnologyLtd with our detailed analytical future growth report. Our valuation report unveils the possibility Anhui Estone Materials TechnologyLtd's shares may be trading at a premium. Caliway Biopharmaceuticals Simply Wall St Growth Rating: ★★★★★☆ Overview: Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries focus on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$208.61 billion. Operations: Caliway Biopharmaceuticals Co., Ltd. generates revenue through its focus on drug development for aesthetic medicine and chronic inflammation. Insider Ownership: 24.2% Earnings Growth Forecast: 93.8% p.a. Caliway Biopharmaceuticals is experiencing significant growth potential, with revenue forecasted to grow at 89% annually, outpacing the Taiwanese market. The company recently gained recognition by being added to the MSCI Global Standard Index and has initiated pivotal Phase 3 trials for its innovative drug CBL-514. Despite a volatile share price and current lack of meaningful revenue, Caliway's strategic advancements in clinical development position it well for future profitability within three years. Delve into the full analysis future growth report here for a deeper understanding of Caliway Biopharmaceuticals. The valuation report we've compiled suggests that Caliway Biopharmaceuticals' current price could be inflated. Key Takeaways Get an in-depth perspective on all 593 Fast Growing Asian Companies With High Insider Ownership by using our screener here. Curious About Other Options? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SEHK:9995 SHSE:688733 and TWSE:6919. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
